Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis

Teresa Coelho(Universidade do Porto), Ole B. Suhr(Umeå University), Brian R. Bettencourt(Alnylam Pharmaceuticals (United States)), Rachel Meyers(Alnylam Pharmaceuticals (United States)), Christina Gamba‐Vitalo(Alnylam Pharmaceuticals (United States)), Joseph Chiesa(Alnylam Pharmaceuticals (United States)), Rick Falzone(Alnylam Pharmaceuticals (United States)), Elizabeth Tranter(Hammersmith Medicines Research), Todd Borland(Alnylam Pharmaceuticals (United States)), Rene Alvarez(Alnylam Pharmaceuticals (United States)), Philip N. Hawkins(The Royal Free Hospital), Jared Gollob(Université Paris-Sud), Javier Martínez Pérez(Hospital de Santo António), Malathy Munisamy(Covance (United Kingdom)), Timothy Mant(IQVIA (United Kingdom)), Valerie A. Clausen(Alnylam Pharmaceuticals (United States)), Pierre Lozeron(Université Paris-Sud), Renta Hutabarat(Alnylam Pharmaceuticals (United States)), Steve Warrington(Hammersmith Medicines Research), Mary Geissler(Alnylam Pharmaceuticals (United States)), Akshay Vaishnaw(Alnylam Pharmaceuticals (United States)), Jamie Harrop(Alnylam Pharmaceuticals (United States)), Ana Silva(Alnylam Pharmaceuticals (United States)), David Adams(Mount Sinai Health System), Qingmin Chen(Shandong University of Political Science and Law), James S. Butler(Alnylam Pharmaceuticals (United States)), Saraswathy V. Nochur(Université Paris-Sud), Kevin Fitzgerald(Epsilon Systems (United States)), Alfica Sehgal(Alnylam Pharmaceuticals (United States)), Jeffrey Cehelsky(Alnylam Pharmaceuticals (United States)), Dinah W.Y. Sah(Port Washington Public Library)
New England Journal of Medicine
August 28, 2013
Cited by 961


Related Papers